Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

BACKGROUND AND OBJECTIVES: Alemtuzumab demonstrated superior efficacy versus subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy was maintained in the 4-year CARE-MS extension, during which alemtuzumab-trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Coles, Alasdair J., Achiron, Anat, Traboulsee, Anthony, Singer, Barry A., Pozzilli, Carlo, Oreja-Guevara, Celia, Giovannoni, Gavin, Comi, Giancarlo, Freedman, Mark S., Ziemssen, Tjalf, Shiota, Debora, Rawlings, Andreea M., Wong, Alana T., Chirieac, Magdalena, Montalban, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515516/
https://www.ncbi.nlm.nih.gov/pubmed/37745914
http://dx.doi.org/10.1177/17562864231194823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515516/
https://www.ncbi.nlm.nih.gov/pubmed/37745914
http://dx.doi.org/10.1177/17562864231194823

Ejemplares similares